Literature DB >> 18541828

Interaction of age with lipoproteins as predictors of aortic valve calcification in the multi-ethnic study of atherosclerosis.

David S Owens1, Ronit Katz, Eric Johnson, David M Shavelle, Jeffrey L Probstfield, Junichiro Takasu, John R Crouse, J Jeffrey Carr, Richard Kronmal, Matthew J Budoff, Kevin D O'Brien.   

Abstract

BACKGROUND: Previous epidemiologic studies have shown that low-density lipoprotein is an independent risk factor for prevalent aortic valve calcification (AVC); however, to our knowledge, the interactions between plasma lipoprotein concentrations and age on the relative risks (RRs) for AVC prevalence and severity have not been examined in a large, racially and ethnically diverse cohort.
METHODS: Using stepwise RR regression, the relationships of baseline fasting lipid levels and lipoprotein levels to baseline prevalence and severity of AVC were determined in 5801 non-statin-using participants in the Multi-Ethnic Study of Atherosclerosis (MESA).
RESULTS: In age-stratified, adjusted analyses, the low-density lipoprotein-associated RRs (95% confidence intervals) for prevalent AVC were higher for younger compared with older participants (age 45-54 years, 1.69 [1.19-2.39]; age 55-64 years, 1.48 [1.24-1.76]; age 65-74 years, 1.09 [0.95-1.25]; and age 75-84 years, 1.16 [0.99-1.36]; P interaction = .04]. There was a similar, significant interaction of age with total cholesterol-associated RR for prevalent AVC (P interaction = .04). In contrast, total- to high-density lipoprotein cholesterol ratio RRs were similar across all age strata (P interaction = .68). At multivariate analyses, no lipoprotein parameter was associated with AVC severity.
CONCLUSIONS: In this racially and ethnically diverse, preclinical cohort, low-density lipoprotein was a risk factor for AVC only in participants younger than 65 years, whereas the total cholesterol/high-density lipoprotein cholesterol ratio was associated with a modest increased risk of AVC across all ages. These findings may have important implications for the efficacy of and targets for dyslipidemia therapies in calcific aortic valve disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18541828      PMCID: PMC4441013          DOI: 10.1001/archinte.168.11.1200

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  53 in total

1.  Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study.

Authors:  J Jeffrey Carr; Jennifer Clark Nelson; Nathan D Wong; Michael McNitt-Gray; Yadon Arad; David R Jacobs; Stephan Sidney; Diane E Bild; O Dale Williams; Robert C Detrano
Journal:  Radiology       Date:  2005-01       Impact factor: 11.105

2.  Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein-related risk of vascular disease.

Authors:  A D Sniderman; I Jungner; I Junger; I Holme; A Aastveit; G Walldius
Journal:  J Intern Med       Date:  2006-05       Impact factor: 8.989

3.  Quantification of coronary artery calcium using ultrafast computed tomography.

Authors:  A S Agatston; W R Janowitz; F J Hildner; N R Zusmer; M Viamonte; R Detrano
Journal:  J Am Coll Cardiol       Date:  1990-03-15       Impact factor: 24.094

4.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis.

Authors:  Luis M Moura; Sandra F Ramos; José L Zamorano; Isabel M Barros; Luis F Azevedo; Francisco Rocha-Gonçalves; Nalini M Rajamannan
Journal:  J Am Coll Cardiol       Date:  2007-01-22       Impact factor: 24.094

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis.

Authors:  G M Novaro; I Y Tiong; G L Pearce; M S Lauer; D L Sprecher; B P Griffin
Journal:  Circulation       Date:  2001-10-30       Impact factor: 29.690

Review 7.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

8.  Expression of HLA-DR antigen and smooth muscle cell differentiation markers by valvular fibroblasts in degenerative aortic stenosis.

Authors:  M Olsson; M Rosenqvist; J Nilsson
Journal:  J Am Coll Cardiol       Date:  1994-12       Impact factor: 24.094

9.  HMG CoA reductase inhibitor (statin) and aortic valve calcium.

Authors:  David M Shavelle; Junichuro Takasu; Matthew J Budoff; SongShou Mao; Xue Qiao Zhao; Kevin D O'Brien
Journal:  Lancet       Date:  2002-03-30       Impact factor: 79.321

10.  Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves.

Authors:  M Olsson; C J Dalsgaard; A Haegerstrand; M Rosenqvist; L Rydén; J Nilsson
Journal:  J Am Coll Cardiol       Date:  1994-04       Impact factor: 24.094

View more
  13 in total

Review 1.  The Pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS.

Authors:  Sammy Elmariah; Emile R Mohler
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

2.  Serum magnesium, phosphorus, and calcium levels and subclinical calcific aortic valve disease: A population-based study.

Authors:  Takashi Hisamatsu; Katsuyuki Miura; Akira Fujiyoshi; Aya Kadota; Naoko Miyagawa; Atsushi Satoh; Maryam Zaid; Takashi Yamamoto; Minoru Horie; Hirotsugu Ueshima
Journal:  Atherosclerosis       Date:  2018-03-22       Impact factor: 5.162

3.  Association of serum phosphate levels with aortic valve sclerosis and annular calcification: the cardiovascular health study.

Authors:  Jason P Linefsky; Kevin D O'Brien; Ronit Katz; Ian H de Boer; Eddy Barasch; Nancy S Jenny; David S Siscovick; Bryan Kestenbaum
Journal:  J Am Coll Cardiol       Date:  2011-07-12       Impact factor: 24.094

4.  Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis.

Authors:  J Gustav Smith; Kevin Luk; Christina-Alexandra Schulz; James C Engert; Ron Do; George Hindy; Gull Rukh; Line Dufresne; Peter Almgren; David S Owens; Tamara B Harris; Gina M Peloso; Kathleen F Kerr; Quenna Wong; Albert V Smith; Matthew J Budoff; Jerome I Rotter; L Adrienne Cupples; Stephen Rich; Sekar Kathiresan; Marju Orho-Melander; Vilmundur Gudnason; Christopher J O'Donnell; Wendy S Post; George Thanassoulis
Journal:  JAMA       Date:  2014-11-05       Impact factor: 56.272

5.  Associations of LV hypertrophy with prevalent and incident valve calcification: Multi-Ethnic Study of Atherosclerosis.

Authors:  Sammy Elmariah; Joseph A C Delaney; David A Bluemke; Matthew J Budoff; Kevin D O'Brien; Valentin Fuster; Richard A Kronmal; Jonathan L Halperin
Journal:  JACC Cardiovasc Imaging       Date:  2012-08

6.  Stages of systemic hypertension and blood pressure as correlates of computed tomography-assessed aortic valve calcium (from the Multi-Ethnic Study of Atherosclerosis).

Authors:  Jason Linefsky; Ronit Katz; Matthew Budoff; Jeffrey Probstfield; David Owens; Junichiro Takasu; David Shavelle; Pamela Ouyang; Bruce Psaty; Kevin D O'Brien
Journal:  Am J Cardiol       Date:  2011-01       Impact factor: 2.778

7.  Associations of long-term and early adult atherosclerosis risk factors with aortic and mitral valve calcium.

Authors:  George Thanassoulis; Joseph M Massaro; Ricardo Cury; Emily Manders; Emelia J Benjamin; Ramachandran S Vasan; L Adrienne Cupple; Udo Hoffmann; Christopher J O'Donnell; Sekar Kathiresan
Journal:  J Am Coll Cardiol       Date:  2010-06-01       Impact factor: 24.094

Review 8.  Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease.

Authors:  Alessandro Mantovani; Stefano Ballestri; Amedeo Lonardo; Giovanni Targher
Journal:  Dig Dis Sci       Date:  2016-01-25       Impact factor: 3.199

Review 9.  Calcification of the heart: mechanisms and therapeutic avenues.

Authors:  Chandana Shekar; Matthew Budoff
Journal:  Expert Rev Cardiovasc Ther       Date:  2018-06-12

10.  Age-modification of lipoprotein, lipid, and lipoprotein ratio-associated risk for coronary artery calcium (from the Multi-Ethnic Study of Atherosclerosis [MESA]).

Authors:  Pathmaja Paramsothy; Ronit Katz; David S Owens; Gregory L Burke; Jeffrey L Probstfield; Kevin D O'Brien
Journal:  Am J Cardiol       Date:  2009-12-22       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.